Neuropace Inc. (NPCE)
NASDAQ: NPCEHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NPCE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $273.89M
- EPS (TTM)
- -$0.56
- Dividend yield
- None
- 52-week range
- 5.46 – 19.60
- Day range
- 7.85 – 8.29
- Volume / Avg
- 749.38K / 270.76K
- Beta
- —
- Shares outstanding
- 34.45M
52-week range
NPCE stock today
Neuropace (NPCE) closed at $7.95 on Nov 20, down 2.33% (-$0.19), versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 749.38K shares, a sign of unusually heavy trading. At this level, NPCE sits near the bottom of its 52-week range of $5.46 to $19.60: 59.4% below the high, set on May 8, 2026 and 45.6% above the low.
NPCE is down 48.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.6%. Neuropace has posted a net loss over the last twelve months (EPS of -$0.56), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neuropace
Company profileNeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Joel D. Becker
- Headquarters
- Mountain View, CA
- Employees
- 216
- IPO year
- 2021
- Website
- neuropace.com
Financial highlights
Full financialsIn fiscal 2025, Neuropace generated $100.0 million in revenue, up 25.1% from fiscal 2024, its 5th consecutive year of revenue growth. Neuropace reported a net loss of $21.5 million, compared with a loss of $27.1 million a year earlier. Gross margin was 77.2% (up from 73.9%) and operating margin -16.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $99.99M | $79.91M | $65.42M | $45.52M | $45.18M |
| Growth | +25.13% | +22.14% | +43.72% | +0.75% | +9.83% |
| Net income | $-21.46M | $-27.14M | $-32.96M | $-47.08M | $-36.08M |
| EPS (diluted) | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$12.22+53.71%
- Strong buy 0
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.11 vs $-0.14
- Surprise
- +21.43%
NPCE news
All NPCE news- Here's Why You Should Retain NeuroPace Stock in Your Portfolio for NowNasdaqNPCE, ISRG, WST, GKOS
- Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?NasdaqNPCE, MDT, LIVN
- NeuroPace Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into NeuroPace (NPCE)PR Newswire
- NeuroPace (NPCE) Q3 2026 Earnings Call TranscriptNasdaq
- NeuroPace, Inc. (NPCE) Reports Q3 Loss, Misses Revenue EstimatesNasdaqNPCE, VEEV
- NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year GuidanceBusiness Wire
- Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?NasdaqALC, NPCE
- NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026Business Wire
Neuropace peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TMCITreace Medical Concepts Inc. | 4.31 | -0.92% | $282.56M | vs NPCE |
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs NPCE |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs NPCE |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs NPCE |
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs NPCE |
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs NPCE |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs NPCE |
| EMBCEmbecta Corp. | 6.02 | -2.75% | $341.09M | vs NPCE |
Indexes, lists and sector
Neuropace stock FAQ
What is Neuropace's stock price today?
NPCE last traded at $7.95 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.
Who is Neuropace's CEO?
Mr. Joel D. Becker is the chief executive officer of Neuropace Inc., which has about 216 employees.
What is the NPCE 52-week high?
The 52-week high for NPCE is $19.60 and the 52-week low is $5.46. The stock is currently 59.4% below its high.